A stabilised analogue of growth hormone-releasing hormone, carrying a trans-3-hexenoyl group on the N-terminus. Studied as a GHRH receptor agonist in the growth hormone axis.
Add sterile bacteriostatic water to the vial to achieve your target working concentration.
Storage conditions: -20°C, dry
Form: Lyophilised
Solubility: Water, BAC water
Current batch: TSM10-260514-200
HPLC purity: 99.66%
MS verified: Yes
Expiry: May 2028
The certificate of analysis for this batch is issued with your order.
C₂₂₁H₃₆₆N₇₂O₆₇S · 5,135.9 Da
Tesamorelin
out of stock
Free shipping on orders over £75
Working out volumes? Peptide calculator · Reconstitution guide
TSM10-260514-200 · HPLC 99.66%
The batch code matches the vial you will receive. Full analysis — purity, mass spectrometry, residual solvents and microbial limits — is issued with your order.
| Content | 10mg |
| Purity | 99.66% HPLC |
| Form | Lyophilised |
| Storage | -20°C, dry |
| Solubility | Water, BAC water |
Same-day dispatch — order within
Same-day dispatch before 3pm, Mon–Fri. Next dispatch .
via Royal Mail Tracked 24
Tesamorelin
10mg · £64.99
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone: the 44-residue human sequence with a trans-3-hexenoyl group attached at the N-terminus, a modification that slows degradation by dipeptidyl peptidase-4. At 5135.9 Da it is one of the larger molecules in this catalogue.
It differs from most compounds here in one important respect. Tesamorelin is an authorised medicine in the United States, approved for HIV-associated lipodystrophy, and the clinical literature — including randomised trials and meta-analyses of them — concerns that supervised medical use, not research material.
Mechanism in the literature
Tesamorelin is described as an agonist at the GHRH receptor on pituitary somatotrophs, stimulating endogenous pulsatile release of growth hormone and, downstream, hepatic IGF-1. Because the action is on the pituitary rather than a direct growth hormone effect, the literature treats the resulting secretion pattern as closer to physiological than exogenous growth hormone administration.
The trial literature cited below concerns an authorised medicine given under medical supervision for a specific licensed indication. It is not evidence about research material, and no efficacy claim is made or implied here. Tesamorelin holds no MHRA marketing authorisation in the United Kingdom.
Handling and reconstitution
Supplied lyophilised at 10mg per vial. Allow the vial to reach room temperature before reconstituting — introducing diluent to cold glass encourages condensation. Add bacteriostatic water down the inner wall rather than onto the cake, and swirl rather than shake; a 44-residue chain is susceptible to shear from vigorous agitation.
Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what permits repeated withdrawals from one vial. Sterile water does not, and is single-use.
Storage and stability
Lyophilised material is held at -20°C and protected from light; the certificate for this batch carries a retest date of May 2028. Reconstituted solution is refrigerated and treated as a short-window preparation measured in weeks rather than months, and repeated freeze-thaw cycling should be avoided.
Common questions
What purity is BSR's Tesamorelin, and how is it verified?
The current batch tests at 99.66% by HPLC against a specification of not less than 98%. Identity is confirmed by LC-MS at 5136.3 Da against a theoretical 5135.90 Da, and the certificate also reports related impurities, water content, residual solvents by GC, heavy metals, bacterial endotoxins and microbial limits.
What is the difference between Tesamorelin and CJC-1295?
Both are GHRH analogues, but they are modified differently. Tesamorelin is the full 44-residue GHRH sequence with a trans-3-hexenoyl group at the N-terminus. CJC-1295 is a shortened GHRH(1-29) fragment with amino acid substitutions, supplied here without DAC. The two are not interchangeable in the literature.
Is Tesamorelin an approved medicine?
Tesamorelin is approved in the United States for HIV-associated lipodystrophy and is supplied there as a prescription medicine. It holds no MHRA marketing authorisation in the United Kingdom. Material sold on this site is research material, not a medicine, and is not for human use.
How should Tesamorelin be stored?
Lyophilised vials are stored at -20°C, protected from light. Once reconstituted with bacteriostatic water the solution is kept refrigerated and used within a short window; avoid repeated freeze-thaw cycles, which degrade peptide material.
Is a certificate of analysis included?
Yes. The certificate for your batch is issued with your order rather than published openly, and covers HPLC purity, mass spectrometry identity, water content, residual solvents, heavy metals and microbial limits.
- Badran A.S. et al. (2026) — Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials, Obes Res Clin Pract
- Russo S.C. et al. (2024) — Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS
- Ditta A.M. et al. (2026) — Efficacy and Safety of Tesamorelin in People Living With HIV With Lipodystrophy: A Systematic Review and Meta-Analysis, J Int Assoc Provid AIDS Care
Cited as research context. BSR has no involvement in these studies and they do not constitute claims about this product.
No reviews of this compound yet. Reviews come only from customers who have bought it.
Sign in to review a compound you have bought.